Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

E2F4 Antikörper

E2F4 Reaktivität: Human, Maus, Ratte WB, IP, IF Wirt: Maus Monoclonal TFE42 unconjugated
Produktnummer ABIN487490
  • Target Alle E2F4 Antikörper anzeigen
    E2F4 (E2F Transcription Factor 4, P107/p130-Binding (E2F4))
    Reaktivität
    • 40
    • 20
    • 17
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    Human, Maus, Ratte
    Wirt
    • 36
    • 4
    • 2
    Maus
    Klonalität
    • 37
    • 5
    Monoklonal
    Konjugat
    • 36
    • 3
    • 2
    • 1
    Dieser E2F4 Antikörper ist unkonjugiert
    Applikation
    • 33
    • 20
    • 13
    • 8
    • 8
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence (IF)
    Spezifität
    This antibody reacts with Human, Mouse and Rat E2F4 on Western blotting and Immunoprecipitation.
    Kreuzreaktivität (Details)
    Species reactivity (tested):Human, Mouse and Rat.
    Produktmerkmale
    Synonyms: E2F-4, Transcription factor E2F4, p107/p130-binding, E2F transcription factor 4
    Aufreinigung
    Protein-A Sepharose Chromatography.
    Immunogen
    Recombinant full-length Human E2F-4. Remarks: Hybridoma was established by fusion of Mouse myeloma cell NS-2 with Balb/cmouse splenocyte
    Klon
    TFE42
    Isotyp
    IgG1
    Top Product
    Discover our top product E2F4 Primärantikörper
  • Applikationshinweise
    Western Blot: 1-5 μg/mL for chemiluminescence detection system. Positive Controls: HL60, Raji, NIH/3T3, C2C12, Rat-1. Immunoprecipitation: 2 μg/200-300 μL of cell extract from 5 x 10^6 cells. Positive Control: HL60. It is reported that this monoclonal antibody can be used in Immunocytochemistry (Ref1). Detailed procedure is provided in Protocols.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Protokoll
    SDS-PAGE & Western Blotting1) Wash the cells 3 times with PBS and suspend with 10 volume of cold Lysis buffer (50 mMTris-HCl, pH 7. 2, 250 mM NaCl, 0. 1% NP-40, 2 mM EDTA, 10% glycerol) containingappropriate protease inhibitors. Incubate it at 4°C with rotating for 30 minutes, thensonicate briefly (up to 10 seconds). 2) Centrifuge the tube at 12,000 x g for 10 minutes at 4°C and transfer the supernatant toanother tube. Measure the protein concentration of the supernatant and add the Lysisbuffer to make 8 mg/mL solution. 3) Mix the sample with equal volume of Laemmli’s sample buffer. 4) Boil the samples for 2 minutes and centrifuge. Load 10 μL of the sample per lane in a 1mm thick SDS-polyacrylamide gel for electrophoresis. 5) Blot the protein to a polyvinylidene difluoride (PVDF) membrane at 1 mA/cm2 for 1 hourin a semi-dry transfer system. (Transfer Buffer: 25 mM Tris, 190 mM glycine, 20% MeOH). See the manufacture's manual for the transfer procedure. 6) To reduce nonspecific binding, soak the membrane in 10% skimmed milk (in PBS, pH7. 2) for 1 hour at room temperature, or overnight at 4°C. 7) Incubate the membrane with primary antibody diluted with PBS, pH 7. 2 containing 1%skimmed milk as suggest in the APPLICATIONS for 1 hour at room temperature. (Theconcentration of antibody will depend on condition. )8) Wash the membrane with PBS (5 minutes x 6 times). 9) Incubate the membrane with the 1: 10000 POD-conjugated anti-mouse IgG diluted with1% skimmed milk (in PBS, pH 7. 2) for 1 hour at room temperature. 10) Wash the membrane with PBS-T (10 minutes x 3 times). 11) Wipe excess buffer from the membrane, then incubate it with appropriatechemiluminescence reagents for 1 minute. Remove extra reagent from the membrane bydabbing with a paper towel, and seal it in plastic wrap. 12) Remove extra reagent from the membrane by dabbing with paper towel, and seal it inplastic wrap. 13) Expose to an X-ray film in a dark room for 3 minutes. 14. Develop the film as usual. The conditions for exposure and development may vary. Positive Controls for Western blotting: HL60, Raji, NIH/3T3, C2C12, Rat-1. Immunoprecipitation1) Wash the cells 3 times with PBS and suspend with 10 volume of cold Lysis buffer (50 mMTris-HCl, pH 7. 2, 250 mM NaCl, 0. 1% NP-40, 2 mM EDTA, 10% glycerol) containingappropriate protease inhibitors. Incubate it at 4°C with rotating for 30 minutes, thensonicate briefly (up to 10 seconds). 2) Centrifuge the tube at 12,000 x g for 10 minutes at 4°C and transfer the supernatant toanother tube. 3) Add primary antibody as suggest in the APPLICATIONS into 300 μL of the supernatant. Mix well and incubate with gentle agitation for 30-120 minutes at 4°C. 4) Add 20 µL of 50% protein A agarose beads resuspended in the cold Lysis buffer. Mix
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1.0 mg/mL
    Buffer
    PBS, pH 7.2 containing 50 % Glycerol without preservatives.
    Konservierungsmittel
    Without preservative
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Store the antibody (in aliquots) at -20 °C. Avoid repeated freezing and thawing.
    Shelf life: one year from despatch.
    Haltbarkeit
    12 months
  • Target
    E2F4 (E2F Transcription Factor 4, P107/p130-Binding (E2F4))
    Andere Bezeichnung
    E2F4 (E2F4 Produkte)
    Synonyme
    E2F-4 antikoerper, 2010111M04Rik antikoerper, AI427446 antikoerper, E2F4 antikoerper, e2f-4 antikoerper, fb72f07 antikoerper, wu:fb72f07 antikoerper, wu:fe05f06 antikoerper, zgc:63815 antikoerper, E2F transcription factor 4 antikoerper, E2F transcription factor 4 S homeolog antikoerper, E2F4 antikoerper, E2f4 antikoerper, e2f4.S antikoerper, e2f4 antikoerper
    Hintergrund
    The E2F family of transcription factors regulates gene expression following heterodimerization with the DP family proteins, which promote transition to S phase from G1 phase. E2F activity is controlled by interactions with the retinoblastoma tumor suppressor family (pRB, p107 and p130). E2F proteins can be divided into three groups on homology and on certain functional characteristics. The first group containing E2F-1, E2F-2 and E2F-3 binds exclusively to pRB and has a cyclin A binding domain that mediates inhibition of DNA binding during entry into S phase. The second group is composed of E2F-4 and E2F-5, which preferentially bind to p107 and p130, although they can bind pRB as well. The last member is E2F-6. E2F-6 appears to act as a transcription repressor. E2F-4 and E2F-5 are functionally different from E2F-1 and E2F-3. E2F-1 and E2F-3 participate in cellular proliferation, whereas E2F-4 and E2F-5 are required for cell cycle arrest in G1 induced by cyclin-dependent kinase inhibitor p16INK4a.Synonyms: E2F transcription factor 4, E2F-4, Transcription factor E2F4, p107/p130-binding
    Gen-ID
    1874
    UniProt
    Q16254
    Pathways
    Zellzyklus, Mitotic G1-G1/S Phases, Regulation of Cell Size
Sie sind hier:
Kundenservice